Please note: AABB reserves the right to make updates to this program.
Wednesday, June 21, 2017- [Rescheduled from 04/05/17]
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 125 (see program format numbers below under Registration)
Educational Track: Quality Education
Topic: Cellular Therapies
Intended Audience: Physicians, Scientists, Nurses, Technologists, Perfusionists, Managers/Supervisors, CEOs/CFOs
Teaching Level: Basic
Director/Moderator: Richard Haspel, MD, PhD, Transfusion Medicine Physician, Beth Israel Deaconess Medical Center, Boston, MA
Speakers: Richard Haspel, MD, PhD, Transfusion Medicine Physician, Beth Israel Deaconess Medical Center, Boston, MA; Brenda Alder, MS, MT(ASCP)SBB, Quality Assurance and Standards Coordinator, Northside Hospital, Atlanta, GA; Edwin Brindle, MSc, MLT(CMLTO), Director, Quality & Regulatory Affairs, Insception Lifebank Cord Blood Program, Mississauga, Ontario, Canada
After participating in this educational activity, participants should be able to:
- Explain the rationale for revised requirements.
- Identify ways to implement the new and revised requirements.
- Identify existing policies, processes, and procedures that may need to be changed in order to conform to the 8th edition.
This program will introduce the 8th Edition of Standards for Cellular Therapy Services. The speakers will summarize the new and revised requirements incorporated into the 8th edition of Standards. These changes include the expansion of informed consent requirements, the addition of a standard to respond to emerging infectious diseases, and the implementation of ISBT 128 labeling of cellular therapy products. In addition, the rationale for the changes will be reviewed.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||